Is my tumor MSI-High or MSS, and how does this affect treatment

Understanding MSI Status and Its Impact on Treatment

Great question! MSI (Microsatellite Instability) status is one of the most important biomarkers in colorectal cancer because it significantly influences treatment decisions, particularly regarding immunotherapy options.

What MSI Status Means

MSI-High (MSI-H) tumors have defects in their DNA mismatch repair system, causing errors to accumulate in repetitive DNA sequences called microsatellites. This creates many mutations that the immune system can recognize.

MSS (Microsatellite Stable) or MSI-Low tumors have intact DNA repair mechanisms and fewer mutations.

How to Find Your MSI Status

Your MSI status should be in your pathology report from your tumor biopsy or surgical specimen. Look for:

• "MSI-High" or "MSI-H"
• "MSS" or "Microsatellite Stable"
• "dMMR" (deficient mismatch repair) - essentially the same as MSI-H
• "pMMR" (proficient mismatch repair) - essentially the same as MSS

If you can't find this information, it may not have been tested yet. According to NCCN Guidelines, MSI testing is recommended for all colorectal cancer patients.

How MSI Status Affects Treatment

If You're MSI-High (~15% of colorectal cancers):

Good news: MSI-H tumors typically respond very well to immunotherapy!

• Better prognosis in early-stage disease
• Immunotherapy options like pembrolizumab (Keytruda) or nivolumab (Opdivo) are highly effective
• May have different chemotherapy recommendations - some studies suggest MSI-H tumors don't benefit as much from certain traditional chemotherapy regimens
• According to NCCN Guidelines, immunotherapy is a preferred first-line option for MSI-H metastatic colorectal cancer

If You're MSS (~85% of colorectal cancers):

• Standard chemotherapy remains the backbone of treatment
• Targeted therapies based on other biomarkers (like KRAS, NRAS, BRAF status) become important
• Immunotherapy alone typically doesn't work well, though clinical trials are exploring combinations

Important Questions to Ask Your Oncologist

1. "Has my tumor been tested for MSI status? If not, can we do that testing?"
2. "Based on my MSI status, what treatment options do you recommend?"
3. "If I'm MSI-High, am I a candidate for immunotherapy instead of or before chemotherapy?"
4. "What other biomarkers should we test for to guide my treatment plan?" (KRAS, NRAS, BRAF, HER2)
5. "Are there clinical trials available that match my MSI status?"

Next Steps

If you can share your pathology report with me (you can upload it), I can help you:

• Locate your MSI status in the report
• Explain what other biomarkers were tested
• Identify what additional testing might be helpful
• Suggest specific questions for your care team

According to the American Cancer Society and NCCN Guidelines, comprehensive biomarker testing (including MSI, KRAS, NRAS, BRAF, and HER2) should be performed on all metastatic colorectal cancers to guide personalized treatment decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.